Novartis: Leukemia, Myeloid, Acute trials
The registry lists 40 Leukemia, Myeloid, Acute studies with Novartis as lead sponsor. 0 are open to participants now and 20 have results posted.
Phase 1 20Phase 2 20Phase 3 2Phase 4 2No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell TransplantTerminatedNCT05447663Phase 1/2Results posted
- Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.TerminatedNCT04623216Phase 1/2Results posted
- A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyTerminatedNCT04150029Phase 2Results posted
- A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)CompletedNCT03512197Phase 3Results posted
- Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.CompletedNCT03379727Phase 3Results posted
- A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AMLCompletedNCT03280030Phase 2Results posted
- A Rollover Study to Provide Continued Treatment With EltrombopagCompletedNCT01957176Phase 4Results posted
- A Safety and Efficacy Study of Eltrombopag in Subjects With AMLCompletedNCT01890746Phase 2Results posted
- Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLCompletedNCT01883362Phase 2Results posted
- BKM120 for Patients With PI3K-activated TumorsCompletedNCT01833169Phase 2Results posted
- Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
- Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute LeukemiaCompletedNCT01826214Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT01440374Phase 2Results posted
- A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).CompletedNCT00946647Phase 1/2Results posted
- Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)CompletedNCT00880269Phase 2Results posted
- A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric LeukemiaTerminatedNCT00866281Phase 1/2Results posted
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
- An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 2Results posted
- PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)CompletedNCT00045942Phase 1/2Results posted
- Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)CompletedNCT05488613
- A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
- Managed Access Programs for PKC412, MidostaurinNo longer availableNCT05219266
- A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.CompletedNCT05155709Phase 1
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
- HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT03940352Phase 1
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnNCT03760445Phase 1/2
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLActive, not recruitingNCT03591510Phase 2
- An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)No longer availableNCT03114228
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
- A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid LeukemiaWithdrawnNCT02826642Phase 1
- Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation ChemotherapyNo longer availableNCT02624570
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
- A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT02078609Phase 1
- A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)CompletedNCT01242774Phase 1
- A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT01055483Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid LeukemiaTerminatedNCT00279773Phase 1
- PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00093600Phase 1